- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02952014
Assessment of a Pre-Workout Dietary Supplement (NB1)
October 30, 2016 updated by: Texas A&M University
Pharmacokinetic, Thermogenic, Hemodynamic, Ergogenic Assessment of a Pre-Workout Dietary Supplement
The purpose of this study is to examine the acute effects of a pre-workout dietary supplement on energy metabolism, cardiovascular hemodynamics, blood metabolites and mental focus.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A number of nutritional strategies have been developed to optimize nutrient delivery prior to exercise.
This includes providing carbohydrate and a number of ergogenic nutrients prior to, during and/or following exercise.
As a result a number of pre-workout supplements have been developed to increase energy availability, promote vasodilation and/or positively affect exercise capacity.
The purpose of this study is to investigate the potential ergogenic value of acute ingestion of a pre-workout dietary supplement prior to exercise.
Study Type
Interventional
Enrollment (Actual)
31
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
College Station, Texas, United States, 77843
- Exercise & Sport Nutrition Laboratory
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- you are an apparently healthy and recreationally active man or woman between the ages of 18 and 40;
- you will need to have at least six months immediate prior history of resistance training on the bench press and leg press or squat;
Exclusion Criteria:
- you have a history of treatment for metabolic disease (i.e., diabetes), hypertension, hypo-tension, thyroid disease, arrhythmia and/or cardiovascular disease;
- you are currently using prescription medications;
- you have an intolerance to caffeine and/or other natural stimulants;
- you are pregnant or a lactating female or plan to become pregnant with the next month;
- you have a history of smoking;
- you drink excessively (i.e., 12 drinks per week or more);
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: C4 Extreme
One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine AKG, 250 mg vitamin C, 150 mg n-acetyle tyrosine, 135 mg caffeine, 7.5 mg l-dopa, 30 mg vitamin B3, 10 mg synephrine, 0.5 mg vitamin B6, 0.25 mg vitamin B9, 0.035 mg vitamin B12.
|
Pre-Workout Dietary Supplement
|
|
Active Comparator: C4 Extreme (without Advantra Z)
One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine AKG, 250 mg vitamin C, 150 mg n-acetyle tyrosine, 135 mg caffeine, 7.5 mg l-dopa, 30 mg vitamin B3, 0.5 mg vitamin B6, 0.25 mg vitamin B9, 0.035 mg vitamin B12.
|
Pre-Workout Dietary Supplement
|
|
Placebo Comparator: Placebo
One dose of flavored placebo (powder mixed with water)
|
Pre-Workout Dietary Supplement
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Optimize nutrient delivery prior to exercise by assessing; cognitive function (i.e., Stroop Color and Word Test and Word Recall Test).
Time Frame: Three weeks
|
Three weeks
|
|
Optimize nutrient delivery prior to exercise by assessing Readiness to Perform Visual Analog Scale.
Time Frame: Three weeks
|
Three weeks
|
|
Optimize nutrient delivery prior to exercise by assessing Resting Energy Expenditure.
Time Frame: Three weeks
|
Three weeks
|
|
Optimize nutrient delivery prior to exercise by assessing Heart Rate.
Time Frame: Three weeks
|
Three weeks
|
|
Optimize nutrient delivery prior to exercise by assessing Blood Pressure.
Time Frame: Three weeks
|
Three weeks
|
|
Optimize nutrient delivery prior to exercise by assessing ECG.
Time Frame: Three weeks
|
Three weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Measure standard clinical chemistry panels in the blood to evaluate safety.
Time Frame: Three weeks
|
Three weeks
|
|
Measure Heart Rate to evaluate safety.
Time Frame: Three weeks
|
Three weeks
|
|
Measure Blood Pressure to evaluate safety.
Time Frame: Three weeks
|
Three weeks
|
|
Measure ECG to evaluate safety.
Time Frame: Three weeks
|
Three weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Richard B Kreider, PhD, Texas A&M University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2014
Primary Completion (Actual)
May 1, 2014
Study Completion (Actual)
May 1, 2014
Study Registration Dates
First Submitted
September 13, 2016
First Submitted That Met QC Criteria
October 30, 2016
First Posted (Estimate)
November 2, 2016
Study Record Updates
Last Update Posted (Estimate)
November 2, 2016
Last Update Submitted That Met QC Criteria
October 30, 2016
Last Verified
October 1, 2016
More Information
Terms related to this study
Other Study ID Numbers
- IRB2014-0022FX
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dietary Modification
-
Brown UniversityNational Cancer Institute (NCI); University of ConnecticutCompletedDietary Habits | Dietary Modification
-
University of ReadingUnknownDietary Habits | Dietary ModificationUnited Kingdom
-
University of ReadingCompletedDietary Habits | Dietary ModificationUnited Kingdom
-
University of ParmaCompletedDietary ModificationItaly
-
University of ParmaCompleted
-
University of ParmaCompletedDietary ModificationItaly
-
University of British ColumbiaCompleted
-
McMaster UniversityCompleted
-
University of GreenwichCompleted
-
University of ParmaCompletedDietary ModificationItaly
Clinical Trials on C4 Extreme
-
Texas A&M UniversityNutraboltCompletedDietary Modification
-
Timothy MullettMerck Sharp & Dohme LLCRecruitingCancer | Health Care UtilizationUnited States
-
University of Louisiana at LafayetteCompletedHuman Performance
-
Vantive Health LLCBaxter Healthcare Corporation; Gambro Renal Products, Inc.Completed
-
Texas A&M UniversityNutraboltCompletedExercise Ergogenics
-
Yale UniversityNational Institute of Mental Health (NIMH)Not yet recruiting
-
Vantive Health LLCBaxter Healthcare Corporation; University of Louisville; Gambro Renal Products...CompletedChronic Kidney Disease | Chronic Renal DiseaseUnited States
-
Escola Superior de Tecnologia da Saúde do PortoNot yet recruiting
-
IRCCS San RaffaeleRecruitingLocalized Prostate CarcinomaItaly
-
Tata Memorial CentreTata Medical CenterActive, not recruitingProstate AdenocarcinomaIndia